InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by BIGHAM MICHAEL, Chairman & CEO. Officer active across 2 companies, notably Adamas Pharmaceuticals Inc. In total, 19 filings have been published. Breakdown: 0 buy · 4 sells. Total volume traded: €97k. History available since 2 June 2021. The latest transaction was disclosed on 2 February 2018 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations19 total
23,255 shares@ US$4.3045.2% of flowCommon StockSEC:0000899243-23-019356:0
156,250 shares0Common StockSEC:0000904454-23-000476:0
45,000 shares0Common StockSEC:0000904454-22-000647:0
19,484 shares@ US$1.9820.7% of flowCommon StockSEC:0000904454-22-000621:0
6,000 shares@ US$3.4711.8% of flowCommon StockSEC:0000904454-22-000526:0
30,000 shares0Common StockSEC:0000904454-22-000504:0
143,182 shares0Common StockSEC:0000904454-22-000423:0
202,500 shares0Common StockSEC:0000904454-22-000262:0
5,059 shares@ US$4.4250.0% of flowCommon StockSEC:0000904454-21-000846:0
5,059 shares@ US$4.4211.2% of flowCommon StockSEC:0000904454-21-000846
10,000 sharesCommon StockSEC:0001328143-21-000095:0
10,000 sharesCommon StockSEC:0001328143-21-000095
75,000 shares0Common StockSEC:0000904454-21-000626:0
75,000 shares0Common StockSEC:0000904454-21-000626
85,909 shares0Common StockSEC:0000904454-21-000514:0
85,909 shares0Common StockSEC:0000904454-21-000514
5,000 shares0Common StockSEC:0001328143-21-000054:0
5,000 shares0Common StockSEC:0001328143-21-000054
30,000 sharesCommon StockSEC:0000904454-16-000934:0
19 of 19 declarations
About BIGHAM MICHAEL
Michael Bigham is the Chairman & CEO of Adamas Pharmaceuticals Inc. and other companies. He leads the operations and strategy of the company, which focuses on developing treatments for neurological diseases. His leadership is crucial in guiding research and development, as well as establishing strategic partnerships in the pharmaceutical sector.
